On January 22, 2026, Joseph Pantginis of HC Wainwright & Co. upgraded Tempest Therapeutics, Inc. (TPST) to a Buy rating, setting a price target of $11. This strong endorsement aligns with the stock’s current trading price of $2.61, suggesting significant upside potential for investors. With volatility coursing through the market, this rating change offers a renewed outlook for opportunities in Tempest’s experimental therapies.
Recent Price Action
In the latest trading sessions, TPST has experienced notable volatility, reflecting the underlying investor sentiment regarding its future prospects. Currently priced at $2.61, the stock has seen a substantial increase of $0.41, or approximately 15.71%, signaling renewed interest. However, the stock’s trajectory has been turbulent, with its 52-week high considerably distanced at $8.75, while the year has painted a stark picture, with a drop of 77.83%. Trade volume has been robust; TPST saw trading activity at 208,949 shares, which eclipses its average volume of 121,793 shares, highlighting heightened investor engagement.
[chart type=’price’ value=’TPST’]
Historical Performance
The historical performance of TPST reveals a troubling pattern amidst the current challenges in the biotech sector. Over the past 30 days, the stock has underperformed—revealing a decline of approximately 11.95%. The quarterly outlook is even bleaker with a staggering drop of 74.56%, signaling serious headwinds. Over the last year, the investor sentiment has softened, matching a year-on-year decline of 77.83%. Volatility metrics illustrate this uncertainty, with a weekly volatility of 7.63% and monthly volatility at 6.06%. These figures indicate that investors should approach TPST with caution while also recognizing the potential for sharp movements driven by market sentiment and company developments.
[chart type=’performance’ value=’TPST’]
Earnings Analysis
The financial performance of Tempest Therapeutics has also played a crucial role in shaping investor outlook. For the most recent earnings period on November 5, 2025, the company reported earnings per share (EPS) of -$0.79, substantially outperforming the consensus estimate of -$3.27. This surprising positive surprise of approximately 75.82% is indicative of the company’s ability to manage expenses and possibly reflects operational efficiencies not anticipated by analysts. However, when compared to the previous earnings report in August, where the EPS was -$2.07 against an estimate of -$3.23, there is a mixed signal about the sustainability of this performance trend. The significant surprise in the latest results bodes well for investor sentiment but raises questions about long-term predictability.
[chart type=’income-bar-chart’ value=’TPST’]
Consensus Ratings
The consensus view among analysts indicates a cautiously optimistic sentiment regarding TPST. After Pantginis’ upgrade, the stock now boasts one Buy rating and no Holds or Sells. The uniform price target set at $11 suggests that analysts fully believe in the stock’s recovery potential, which could provide a remarkable opportunity for those willing to invest despite the underlying risks. The singular focus on a Buy rating underscores the confidence from HC Wainwright & Co. regarding Tempest’s forthcoming developments and their impact on market performance.
[chart type=’analyst-ratings’ value=’TPST’]
Stock Grading or Fundamental View
Tempest Therapeutics currently holds a Stocks Telegraph (ST) Score of 25, reflecting a challenging investment environment for the company at this time. This score signals potential weaknesses in its fundamentals or market position relative to peers in the biotechnology sector. Investors may want to take note of this quantitative insight when considering their investment in TPST, as it indicates a need for reevaluation of strategic positioning and operational execution.
[chart type=’st-cards’ value=’TPST’]
Conclusion
Tempest Therapeutics represents a high-risk, high-reward opportunity within the current investment landscape. The recent upgrade to a Buy rating coupled with a significant price target suggests that this stock may attract those looking for potential long-term growth. However, prospective investors should remain aware of the inherent risks, including recent performance volatility and its aggressive historical declines. With its current position presenting opportunities and threats alike, TPST could suit those investors willing to navigate a bumpy road for high upside potential. Thus, it is essential to keep Tempest on the radar while monitoring industry trends and company-specific developments closely.